Repinotan: Difference between revisions
CSV import |
CSV import |
||
| Line 24: | Line 24: | ||
{{stub}} | {{stub}} | ||
== Repinotan == | |||
<gallery> | |||
File:Repinotan.svg|Repinotan | |||
File:Repinotan Dose Relationship to Nociception.png|Repinotan Dose Relationship to Nociception | |||
File:Repinotan synthesis.svg|Repinotan Synthesis | |||
</gallery> | |||
Latest revision as of 01:22, 20 February 2025
Repinotan is a 5-HT1A receptor agonist that was under development by Bayer for the potential treatment of cerebral ischemia and stroke. It reached phase II clinical trials but was discontinued.
History[edit]
Repinotan was first developed by Bayer, a German multinational pharmaceutical and life sciences company. It was initially investigated for its potential use in the treatment of cerebral ischemia and stroke. However, despite reaching phase II clinical trials, the development of Repinotan was eventually discontinued.
Mechanism of Action[edit]
Repinotan acts as an agonist at the 5-HT1A receptor. 5-HT1A receptors are a subtype of the 5-HT receptor that bind the endogenous neurotransmitter serotonin. They are located in the central and peripheral nervous system and are believed to play a key role in the regulation of mood and anxiety.
Clinical Trials[edit]
Repinotan underwent phase II clinical trials for its potential use in the treatment of cerebral ischemia and stroke. However, the trials did not yield the desired results, leading to the discontinuation of the drug's development.
Discontinuation[edit]
Despite the initial promise, the development of Repinotan was discontinued. The reasons for this are not publicly disclosed, but it is common for drugs to be discontinued due to factors such as lack of efficacy, safety concerns, or commercial reasons.
